Q3 2025 Earnings Call Transcript November 3, 2025 Vertex, Inc. reports earnings inline with expectations. Reported EPS is ...

The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...

EXCLUSIVE: The Express has campaigned for cystic fibrosis sufferers for six years but now a charity is highlighting the CF ...

AI is revolutionizing how the Department of Homeland Security protects the U.S. via better border and airport security, as examples.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) in Q3 CY2025, with sales up 11% year on year to $3.08 billion. The ...

The titans of artificial intelligence have been cutting massive deals among themselves—and investors are getting anxious.

Vertex (VERX) remains unprofitable but is narrowing its losses at an average rate of 16.4% per year over the past five years. Looking ahead, the company’s annual revenue is expected to grow by 12.4% ...

Vertex Pharmaceuticals (VRTX) is rated as a "Strong Buy" due to robust revenue growth and multiple expansion opportunities ...

Vertex (NASDAQ: VERX) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table below ...

Election Day, or the general election, is Tuesday, Nov. 4. In the general election, voters will consider statewide ...

A new consensus report on the management of type 1 diabetes in adults was presented recently at the European Association for ...